{"name": "Durata Therapeutics",
 "permalink": "durata-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/durata-therapeutics",
 "homepage_url": "http://www.duratatherapeutics.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": 55,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@duratatherapeutics.com",
 "phone_number": "312 219 7000",
 "description": "",
 "created_at": "Wed Dec 23 06:01:11 UTC 2009",
 "updated_at": "Mon May 13 05:54:50 UTC 2013",
 "overview": "\u003Cp\u003EDurata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners.\u003C/p\u003E\n\n\u003Cp\u003EDurata is focused on Vicuron\u00e2\u20ac\u2122s antibiotic drug candidate, dalbavancin. Its product portfolio also includes two preclinical antibiotic programs while Pfizer will retain the marketed anti-fungal agent, EraxisTM, which was formerly owned by Vicuron.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[147,
       102],
      "assets/images/resized/0010/6506/106506v1-max-150x150.png"],
     [[147,
       102],
      "assets/images/resized/0010/6506/106506v1-max-250x250.png"],
     [[147,
       102],
      "assets/images/resized/0010/6506/106506v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Paul",
      "last_name": "R Edick",
      "permalink": "paul-r-edick",
      "image": null}},
   {"is_past": false,
    "title": "CMO",
    "person":
     {"first_name": "Michael",
      "last_name": "Dunne",
      "permalink": "michael-dunne",
      "image": null}},
   {"is_past": false,
    "title": "COO",
    "person":
     {"first_name": "Corey",
      "last_name": "N. Fishman",
      "permalink": "corey-n-fishman",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": null,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://www.finsmes.com/2009/12/newly-formed-durata-therapeutics.html",
    "source_description": "Newly Formed Durata Therapeutics Acquires Vicuron Pharmaceuticals from Pfizer",
    "acquired_year": 2009,
    "acquired_month": 12,
    "acquired_day": 21,
    "company":
     {"name": "Vicuron Pharmaceuticals",
      "permalink": "vicuron-pharmaceuticals",
      "image": null}}],
 "offices":
  [{"description": "",
    "address1": "89 Headquarters Plaza North",
    "address2": "Suite 306 ",
    "zip_code": "07960 ",
    "city": "Morristown",
    "state_code": "CT",
    "country_code": "USA",
    "latitude": null,
    "longitude": null},
   {"description": "R\u0026D Headquarters",
    "address1": "322 East Main Street",
    "address2": "",
    "zip_code": "06405",
    "city": "Branford",
    "state_code": "CT",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Durata Therapeutics Files For IPO (DRTX)",
    "stoned_year": 2012,
    "stoned_month": 3,
    "stoned_day": 22,
    "source_url": "http://www.businesswire.com/news/home/20120322006678/en/Durata-Therapeutics-Files-Registration-Statement-Proposed-Initial",
    "source_text": null,
    "source_description": "Business Wire",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Durata Therapeutics",
      "permalink": "durata-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}